Quick summary
FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 interaction that keeps them alive. A landmark 2017 Cell paper showed it restored fitness, hair density, and kidney function in aged mice.
Overview
FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide designed to selectively eliminate senescent cells — aged, dysfunctional cells that accumulate with age and drive chronic inflammation. By disrupting the FOXO4-p53 protein interaction that keeps senescent cells alive, FOXO4-DRI triggers apoptosis specifically in senescent cells without affecting healthy surrounding tissue. It represents one of the most targeted senolytic approaches in aging biology research.
Mechanism of action
Senescent cells resist apoptosis in part because FOXO4 sequesters p53 in the nucleus, preventing p53 from translocating to mitochondria and initiating cell death. FOXO4-DRI is a cell-penetrating peptide that competitively binds FOXO4, disrupting the FOXO4-p53 interaction. This releases p53, allowing it to translocate to the mitochondrial outer membrane where it activates the intrinsic apoptosis pathway via Bax/Bak pore formation and cytochrome c release. Crucially, because healthy cells do not depend on this FOXO4-p53 survival axis, FOXO4-DRI selectively clears senescent cells while leaving non-senescent cells intact. The retro-inverso D-amino acid structure confers protease resistance, enhancing in vivo stability compared to L-peptide equivalents.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Senescent cell clearance (preclinical mouse protocol) | subcutaneous | 5–5 mg/kg | every other day for 3 doses | Mouse study protocol only. No validated human equivalent exists. Human dosing entirely extrapolated and unvalidated. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The landmark 2017 Cell paper by Baar et al. demonstrated that FOXO4-DRI at 5 mg/kg (IP, every other day x3) restored fitness, hair density, and kidney function in chemotherapy-aged and naturally aged mice. Subsequent studies confirmed senolytic activity in human chondrocytes (relevant to osteoarthritis), senescent Leydig cells (testosterone restoration in aged mice), senescent endothelial cells, and keloid fibroblasts. No human clinical trials have been completed. Pharmacokinetic data in humans — plasma half-life, tissue distribution, clearance — is entirely unknown. Unity Biotechnology has explored senolytic approaches though FOXO4-DRI is not their lead compound.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with FOXO4-DRI for synergistic effects.
Legal status
Research chemical with no FDA-approved indication. No IND filed as of 2026. Available only for preclinical research purposes. Not approved for human use anywhere.
Sourcing & access
Research compound
FOXO4-DRI is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
FOXO4-DRI is a cell-penetrating senolytic peptide made from D-amino acids in a retro-inverso configuration for protease resistance. It selectively triggers apoptosis in senescent cells without affecting healthy tissue by disrupting the FOXO4-p53 survival axis.
Senescent cells survive because FOXO4 sequesters p53 in the nucleus. FOXO4-DRI competitively binds FOXO4, releasing p53 to translocate to mitochondria and activate the intrinsic apoptosis pathway via Bax/Bak pore formation. Healthy cells do not depend on this axis and are spared.
No human safety data exists. Animal studies suggest potential off-target apoptosis in non-senescent cells at high doses. No human clinical trials have been completed, no IND has been filed, and human pharmacokinetic data is entirely unknown.
The 2017 Cell paper by Baar et al. showed that FOXO4-DRI at 5 mg/kg (every other day for 3 doses) restored fitness, hair density, and kidney function in both chemotherapy-aged and naturally aged mice. Subsequent studies confirmed senolytic activity in human chondrocytes and senescent Leydig cells.
Research references
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and AgingPubMed
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human ChondrocytesPubMed
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathwayPubMed
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylationPubMed